Literature DB >> 27513223

Comparison of the Tolerability of Diclofenac and Nepafenac.

Asaf Achiron1,2, Lily Karmona1,2, Michael Mimouni3, Assaf Gershoni2,4, Yana Dzhanov1,2, Zvi Gur5, Zvia Burgansky1,2.   

Abstract

PURPOSE: Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the prevention and treatment of inflammation and pain following cataract surgery. Preservative-free diclofenac and nepafenac drops are commonly used ophthalmic NSAIDs. The purpose of this study was to compare the tolerability of diclofenac to that of nepafenac.
METHODS: In this prospective patient-blinded study, consecutive patients undergoing cataract surgery were included. One drop of nepafenac 0.1% and diclofenac sodium 0.1% were instilled in the right and left eyes, respectively, one immediately after the other, 1 day before surgery. Visual analog scale (scale 0-10) was used to measure patient discomfort, itching, burning, and pain at 1 second (s), 15 s, 1 minute (min), and 5 min postadministration.
RESULTS: Overall, 44 eyes of 22 patients were included in this study. Diclofenac and nepafenac had high and similar tolerability at all time points with no significant difference regarding all aspects of tolerability. A vast majority of patients (72%) did not prefer 1 drop over the other in terms of overall comfort.
CONCLUSIONS: Both diclofenac and nepafenac seem to have similar high tolerability. Diclofenac may be an affordable alternative to nepafenac and therefore should be considered by prescribing physicians, specifically in preoperative cataract patients.

Entities:  

Keywords:  Diclofenac; NSAID; Nepafenac; tolerability

Mesh:

Substances:

Year:  2016        PMID: 27513223     DOI: 10.1089/jop.2016.0057

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  1 in total

1.  Efficacy of Pretreatment with Preservative-Free Topical Bromfenac in Improving Post-Intravitreal-Injection Pain: A Prospective Pilot Study.

Authors:  Dong-Hyun Lee; Minha Kim; Eun-Young Choi; Hee-Seung Chin; Min Kim
Journal:  J Clin Med       Date:  2022-07-18       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.